Sun Pharma Q1 FY27: Profit up 27%, margins at 80.5%

Key takeaway from the quarter

Sun Pharmaceutical Industries Ltd reported double-digit growth in Q1 FY27 consolidated sales, with improvement in gross margin and a sharp year-on-year rise in reported profit. The company said momentum in India and growth in Global Innovative Medicines supported performance during the quarter ended June 30, 2026. At the same time, management commentary and reported data pointed to continued weakness in the U.S. generics business, which weighed on overall growth.

The company hosted its Q1 FY27 earnings conference call on July 31, 2026, where senior management discussed quarterly performance and fielded investor questions. The transcript and webcast access details were shared through company communications, with the full call transcript available through the published event transcript.

Consolidated sales and margin movement

Sun Pharma’s sales excluding other operating revenue rose 10.1% year-on-year to ₹151.836 billion in Q1 FY27. Revenue from operations increased 10.5% year-on-year to ₹152.999 billion, compared with ₹138.514 billion a year earlier.

Gross margin expanded to 80.5% for the quarter, which the company attributed mainly to a better product mix versus the same period last year. This gross margin improvement was one of the key operating positives highlighted in the quarter’s update.

However, at the EBITDA line, growth was modest compared with sales. EBITDA rose 2.7% year-on-year to ₹44.177 billion, while the EBITDA margin declined to 28.9% from 31.1% in the year-ago quarter, reflecting higher costs relative to income.

Profit rose 27%, but adjusted profit growth was lower

Reported consolidated net profit after tax for Q1 FY27 was ₹28.948 billion, a 27% increase year-on-year. Net profit attributable to owners was reported at ₹28.948 billion for the quarter ended June 30, 2026, versus ₹22.786 billion in the year-ago period.

Adjusted net profit was ₹30.894 billion, up 3.1% year-on-year from ₹29.961 billion. The difference between reported and adjusted profit reflected exceptional items booked during the quarter. Basic and diluted earnings per share increased to ₹12.10 from ₹9.50.

The company also reported profit before exceptional items and tax at ₹43.029 billion, up 7.8% year-on-year. After exceptional items, profit before tax increased 29.2% year-on-year to ₹40.988 billion.

Expenses rose faster than income

Total expenses increased 13.5% year-on-year to ₹117.206 billion, outpacing the growth in total income. This higher cost growth was consistent with the EBITDA margin contraction to 28.9%.

While gross margin widened, the expense trajectory highlights why operating leverage was limited in the quarter despite healthy top-line growth. The quarter’s mix improvement benefited gross profitability, but did not fully translate into higher operating margins.

India formulations led growth and lifted share of sales

India formulations sales increased 16% year-on-year to ₹54.749 billion, compared with ₹47.211 billion in the year-ago quarter. India contributed 36.1% of consolidated sales in Q1 FY27, underscoring the segment’s role as a key growth engine for the company.

Sun Pharma also reported that it became the number two generic semaglutide injectable player in India during the quarter and held an 8.5% market share in the Indian pharmaceutical market, as per the quarter update. The company launched five new products in India during Q1 FY27.

Global Innovative Medicines grew to $1.351 billion

Global Innovative Medicines sales grew 12.8% to 12.9% year-on-year to $1.351 billion in Q1 FY27 (from $1.311 billion). The business accounted for 21.9% of total sales in the quarter.

The company attributed growth to strong performance of products including Ilumya, Odomzo, and Cequa across U.S. and ex-U.S. markets. Management also highlighted the contribution of innovative medicines as an important offset to weaker trends elsewhere in the portfolio.

U.S. business remained a pressure point

Sun Pharma indicated that the U.S. business declined 9.7% during the quarter, even as branded generics and innovative medicines supported consolidated performance. This weakness in the U.S. generics business was also cited as a factor limiting overall growth.

Alongside its India launches, Sun Pharma said it launched five generic products in the U.S. during Q1 FY27, positioning the portfolio for future quarters.

Exceptional items: Organon-related costs and labour codes

The company recorded exceptional charges of ₹2.041 billion in Q1 FY27. These included ₹1.670 billion in due-diligence, legal, filing and other costs related to the proposed Organon acquisition, and ₹0.371 billion linked to India’s New Labour Codes.

A related tax credit of ₹0.094 billion reduced the after-tax impact of these exceptional charges to ₹1.947 billion, according to the quarter’s disclosures.

Street expectations and investor reaction points

Despite the strong year-on-year increase in reported profit, Sun Pharma’s results were reported as below Street expectations on revenue and net profit. Reported revenue of ₹152.999 billion compared with a Street expectation of ₹156.250 billion, and reported net profit of ₹28.948 billion compared with an expectation of ₹30.510 billion.

EBITDA of ₹44.177 billion was above the expectation of ₹42.550 billion, and the EBITDA margin of 28.9% exceeded the expected 27.2%, based on the poll figures shared in the report.

Q1 FY27 snapshot (normalized units)

Management commentary and guidance

Kirti Ganorkar, Managing Director of Sun Pharma, said the quarter’s performance was driven by strong momentum in India and robust growth in Innovative Medicines across the U.S. and international regions.

Management maintained full-year revenue growth guidance at “high single digits,” as stated in the quarter update. The company’s near-term narrative continues to balance strong India performance and innovative medicines growth against softer trends in the U.S. generics business.

What to watch next

For investors, the next set of cues will likely come from the company’s commentary on its U.S. business trajectory, pace of product launches, and updates related to costs tied to the proposed Organon acquisition. The company has also indicated that the earnings call transcript and related materials would be made available through its website for reference.

The quarter closed with improved gross margin and stronger reported profit, but with operating margin compression and a reported miss versus consensus on revenue and net profit, keeping attention on execution in the coming quarters.